Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

NCT05605535 is registered in ClinicalTrials.gov with CanariaBio Inc. as lead sponsor.

NCT NCT05605535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05605535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Lead sponsor
CanariaBio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 7, 2023
Completion date
September 15, 2027
Enrollment
88 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian cancer, ovarian neoplasm epithelial, ovarian serous adenocarcinoma, peritoneal carcinoma